



564 PATIENTS WITH HYPERPHOSPHATEMIA RECEIVING MAINTENANCE DIALYSIS

Baseline characteristics during the RTP



PRIMARY ENDPOINT

Difference in the change in serum P between tenapanor and placebo from the beginning to end of the RWP in the efficacy analysis set.



SAFETY AND TOLERABILITY


Patients reporting diarrhea during the RTP (tenapanor vs sevelamer carbonate):



Serious adverse events during the RTP (tenapanor vs sevelamer carbonate):




TRIAL DESIGN



SECONDARY ENDPOINT: CHANGE IN SERUM P OVER THE RTP



In the **ITT POPULATION**, mean serum P decreased from **7.4 mg/dL** at period-specific baseline to **5.9 mg/dL** at week 26, with a mean (SD) decrease of **1.4 (1.8) mg/dL**



STUDY LIMITATIONS

- Conclusions drawn from the responder analysis have limited generalizability
- These results should be interpreted with caution as this part of the trial was open label with no placebo control